IONS

Ionis Pharmaceuticals

IONS

Attention (50-day avg)0%

Attention rank (50-day avg)#725

Bullish sentiment (50-day avg)40%

Price to earnings ratio-19.1

Market capitalization7.6B

Earnings per share-3.48

Dividend yield (TTM)—

Revenue (annual)943.7M

Net income (annual)-381.4M

Social

What share of all stock conversation is about IONS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0.01% +0	0% 0

Sep 23

Ionis Pharmaceuticals and partner Roche announced positive interim Phase 3 results for sefaxersen in IgA nephropathy, with the drug achieving a statistically significant and clinically meaningful reduction in proteinuria at Week 37.
The study, part of the IMAgINATION program, met its primary endpoint, and the results suggest sustained execution and potential progression milestones for the Ionis-Roche collaboration.
The data also indicates the RNA-targeting therapy could improve kidney function and open the path to a swift FDA nod, with the drug reducing protein in the urine and showing a statistically significant and clinically meaningful reduction in proteinuria versus placebo.

Generated by AI

Sentiment

Of the messages about IONS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	45.45% +41.75	34.02% -54.14	69.06% -1.68
Bearish	—	54.55% -41.75	65.98% +54.14	30.94% +1.68

Bullish· Sep 2

Ionis Pharmaceuticals' triglyceride-lowering drug showed significant results in a pair of late-stage trials, cutting triglycerides by 72% and slashing pancreatitis risk by 85%.
The company's shares surged 34% on Phase 3 data, with RBC calling it "an absolute home run" and estimating $2.5B peak sales potential.
Ionis Pharmaceuticals has a strong pipeline momentum, with a new revenue stream from its RNA prophylactic for hereditary angioedema, and is planning to file a supplemental NDA with the FDA by year-end.

Bearish· Mar 23

Ionis Pharmaceuticals' tominersen Phase 3 study for Huntington's disease was paused, leading to a significant drop in the stock price.
Analysts have lowered their price targets for Ionis Pharmaceuticals, with some citing concerns over the company's ability to deliver on its pipeline of treatments.
The stock's decline is seen as justified, with some arguing that the company's failure to deliver on tominersen was a significant setback that will have lasting consequences.

Generated by AI

Topics

Of the messages about IONS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	97.8%	93.82%	69.25%
Analysts	—	2.2%	0.81%	11.83%
Macro	—	0%	0%	4.25%
Controversies	—	0%	1.61%	5.36%
Earnings	—	0%	3.49%	3.39%
Technical Analysis	—	0%	0.27%	5.91%

Earnings· Aug 8

Ionis Pharmaceuticals, Inc. ($IONS) reported FQ2 earnings of -$0.09 EPS, missing estimates by $0.06.
The company beat revenue estimates, posting $104.15M in revenue.
Ionis Pharmaceuticals also missed the Estimize EPS Consensus by $0.04 and beat the Estimize Revenue Consensus by $12.59M.

Analysts· Mar 23

SVB Leerink analyst maintains Ionis Pharmaceuticals with a Market Perform and lowers the price target from $50 to $36.
Analysts at Needham & Company LLC, BMO Capital Markets, and Needham & Company LLC have maintained a Buy rating for Ionis Pharmaceuticals with price targets of $95, $90, and $86 respectively.
SVB Leerink has maintained a Market Perform rating for Ionis Pharmaceuticals, while Barclays, Morgan Stanley, and Piper Sandler have lowered their price targets to $47, $43, and $45 respectively.

Announcements· Aug 21

Ionis Pharmaceuticals' ($IONS) DAWNZERA (donidalorsen) has been approved by the US FDA as the first and only RNA-targeted prophylactic treatment for hereditary angioedema (HAE).
DAWNZERA is designed to prevent HAE attacks in adult and pediatric patients aged 12 and older, with self-administered dosing every 4 or 8 weeks, offering the longest dosing interval available.
The FDA approval has driven a 22.2% YTD increase in $IONS stock, with the company also announcing a price target lift to $43 by Stifel following the approval.

Generated by AI

Community

Of the messages about IONS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	67.65%	81.11%	55.18%
Newcomers	100%	32.35%	18.89%	44.82%

Regulars· Sep 23

Ionis Pharmaceuticals' partner Roche announced positive interim results from a Phase 3 study for sefaxersen, an RNA-targeted therapy for IgA nephropathy (IgAN), achieving significant proteinuria reduction at week 37.
The study's primary endpoint was met with statistically significant and clinically meaningful reductions in proteinuria versus placebo, and safety results were in line with expectations.
The encouraging data from the IMAgINATION study could lead to a swift FDA nod for sefaxersen, and Ionis now has 9 active Phase 3 trials.

Newcomers· Sep 4

Newcomers are focused on the failed endpoint of Ionis Pharmaceuticals' pelacarsen in patients with elevated Lp(a) and established cardiovascular disease, highlighting immediate market attention to the program and potential downstream milestones.
The FDA approved Ionis' ZANVASTRO, the first disease-modifying treatment for Alexander disease, a rare genetic disorder, and one fund holding its maker has a significant portion of its portfolio in a money market account.
Ionis has several upcoming tests, including a larger study of GSK's bepirovirsen, a hepatitis B drug discovered by Ionis, and results from the pelacarsen heart-disease study, which could lead to a potential royalty stream if the data are strong.

Generated by AI

Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investors is how well the current valuation lines up with the sales its business is generating and may be able to support over time. The stock is down about 45.0% year to date. This puts a sharp spotlight on whether today's market value still lines up with what Ionis can justify through its sales...

5d agoYahoo Finance

Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

5d agoYahoo Finance

H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data

5d agoInvesting.com

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

6d agoThe Globe and Mail

Oppenheimer reiterates Ionis stock rating on late-stage wins

6d agoInvesting.com

Roche, Ionis RNA drug scores in kidney disease study

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

6d agoYahoo Finance

Also Discussed

Investors talking about IONS also mention

#	Name	Attention
1	Alnylam Pharmaceuticals, Inc.ALNY	0%0
2	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
3	Biogen IncBIIB	0%-0.01
4	Agios Pharmaceuticals, Inc.AGIO	0%0
5	BioMarin Pharmaceutical IncBMRN	0%+0
6	Incyte Corp.INCY	0%new
7	iShares Biotechnology ETFIBB	0.01%0
8	Novartis AG Sponsored ADRNVS	0%-0.01
9	SGEN - Seagen Inc.	——
10	Neurocrine Biosciences, Inc.NBIX	0%new

Ionis Pharmaceuticals, Inc.

Healthcare
Biotechnology

Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines. Using its proprietary antisense technology, Ionis creates therapies designed to modulate gene expression and address serious diseases, particularly in neurology and cardiometabolic care, as well as other high-need therapeutic areas. The company currently markets several medicines for conditions such as spinal muscular atrophy, hereditary amyloidosis, amyotrophic lateral sclerosis, and certain rare cardiovascular and metabolic disorders. Ionis also maintains an active pipeline of investigational programs and collaborates with pharmaceutical partners to expand the reach of its platform. Headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a significant role in the biotechnology market as a leading developer of RNA-based therapeutics.

Website

Location

2855 Gazelle Court

Carlsbad, CA, 92010

United States

Social

What share of all stock conversation is about IONS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0.01% +0	0% 0

Sep 23

Ionis Pharmaceuticals and partner Roche announced positive interim Phase 3 results for sefaxersen in IgA nephropathy, with the drug achieving a statistically significant and clinically meaningful reduction in proteinuria at Week 37.
The study, part of the IMAgINATION program, met its primary endpoint, and the results suggest sustained execution and potential progression milestones for the Ionis-Roche collaboration.
The data also indicates the RNA-targeting therapy could improve kidney function and open the path to a swift FDA nod, with the drug reducing protein in the urine and showing a statistically significant and clinically meaningful reduction in proteinuria versus placebo.

Generated by AI

Sentiment

Of the messages about IONS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	45.45% +41.75	34.02% -54.14	69.06% -1.68
Bearish	—	54.55% -41.75	65.98% +54.14	30.94% +1.68

Bullish· Sep 2

Ionis Pharmaceuticals' triglyceride-lowering drug showed significant results in a pair of late-stage trials, cutting triglycerides by 72% and slashing pancreatitis risk by 85%.
The company's shares surged 34% on Phase 3 data, with RBC calling it "an absolute home run" and estimating $2.5B peak sales potential.
Ionis Pharmaceuticals has a strong pipeline momentum, with a new revenue stream from its RNA prophylactic for hereditary angioedema, and is planning to file a supplemental NDA with the FDA by year-end.

Bearish· Mar 23

Ionis Pharmaceuticals' tominersen Phase 3 study for Huntington's disease was paused, leading to a significant drop in the stock price.
Analysts have lowered their price targets for Ionis Pharmaceuticals, with some citing concerns over the company's ability to deliver on its pipeline of treatments.
The stock's decline is seen as justified, with some arguing that the company's failure to deliver on tominersen was a significant setback that will have lasting consequences.

Generated by AI

Topics

Of the messages about IONS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	97.8%	93.82%	69.25%
Analysts	—	2.2%	0.81%	11.83%
Macro	—	0%	0%	4.25%
Controversies	—	0%	1.61%	5.36%
Earnings	—	0%	3.49%	3.39%
Technical Analysis	—	0%	0.27%	5.91%

Earnings· Aug 8

Ionis Pharmaceuticals, Inc. ($IONS) reported FQ2 earnings of -$0.09 EPS, missing estimates by $0.06.
The company beat revenue estimates, posting $104.15M in revenue.
Ionis Pharmaceuticals also missed the Estimize EPS Consensus by $0.04 and beat the Estimize Revenue Consensus by $12.59M.

Analysts· Mar 23

SVB Leerink analyst maintains Ionis Pharmaceuticals with a Market Perform and lowers the price target from $50 to $36.
Analysts at Needham & Company LLC, BMO Capital Markets, and Needham & Company LLC have maintained a Buy rating for Ionis Pharmaceuticals with price targets of $95, $90, and $86 respectively.
SVB Leerink has maintained a Market Perform rating for Ionis Pharmaceuticals, while Barclays, Morgan Stanley, and Piper Sandler have lowered their price targets to $47, $43, and $45 respectively.

Announcements· Aug 21

Ionis Pharmaceuticals' ($IONS) DAWNZERA (donidalorsen) has been approved by the US FDA as the first and only RNA-targeted prophylactic treatment for hereditary angioedema (HAE).
DAWNZERA is designed to prevent HAE attacks in adult and pediatric patients aged 12 and older, with self-administered dosing every 4 or 8 weeks, offering the longest dosing interval available.
The FDA approval has driven a 22.2% YTD increase in $IONS stock, with the company also announcing a price target lift to $43 by Stifel following the approval.

Generated by AI

Community

Of the messages about IONS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	67.65%	81.11%	55.18%
Newcomers	100%	32.35%	18.89%	44.82%

Regulars· Sep 23

Ionis Pharmaceuticals' partner Roche announced positive interim results from a Phase 3 study for sefaxersen, an RNA-targeted therapy for IgA nephropathy (IgAN), achieving significant proteinuria reduction at week 37.
The study's primary endpoint was met with statistically significant and clinically meaningful reductions in proteinuria versus placebo, and safety results were in line with expectations.
The encouraging data from the IMAgINATION study could lead to a swift FDA nod for sefaxersen, and Ionis now has 9 active Phase 3 trials.

Newcomers· Sep 4

Newcomers are focused on the failed endpoint of Ionis Pharmaceuticals' pelacarsen in patients with elevated Lp(a) and established cardiovascular disease, highlighting immediate market attention to the program and potential downstream milestones.
The FDA approved Ionis' ZANVASTRO, the first disease-modifying treatment for Alexander disease, a rare genetic disorder, and one fund holding its maker has a significant portion of its portfolio in a money market account.
Ionis has several upcoming tests, including a larger study of GSK's bepirovirsen, a hepatitis B drug discovered by Ionis, and results from the pelacarsen heart-disease study, which could lead to a potential royalty stream if the data are strong.

Generated by AI

Ionis Pharmaceuticals

Social

Sep 23

Bullish· Sep 2

Bearish· Mar 23

Earnings· Aug 8

Analysts· Mar 23

Announcements· Aug 21

Regulars· Sep 23

Newcomers· Sep 4

Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide

Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis

H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)

Oppenheimer reiterates Ionis stock rating on late-stage wins

Roche, Ionis RNA drug scores in kidney disease study

Also Discussed

Ionis Pharmaceuticals, Inc.

Company Information

Location

Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide

Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis

H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)

Oppenheimer reiterates Ionis stock rating on late-stage wins

Roche, Ionis RNA drug scores in kidney disease study

Also Discussed

Social

Sep 23

Bullish· Sep 2

Bearish· Mar 23

Earnings· Aug 8

Analysts· Mar 23

Announcements· Aug 21

Regulars· Sep 23

Newcomers· Sep 4